Is retatrutide available to the public?

Retatrutide is not FDA-approved and is not legally available outside of clinical trials. Some providers may offer it under research or "off-label investigational" frameworks, but this carries significant legal and safety risk. Verify any provider's authorization carefully.

When might retatrutide receive FDA approval?

Phase III trials are ongoing as of 2026. FDA approval, if granted, would follow Phase III completion and NDA review — typically 1–3 years after Phase III initiation. Monitor ClinicalTrials.gov for updates.

Home›Legal›Retatrutide in Texas

Educational — Not Legal AdviceUpdated May 10, 2026

Retatrutide in Texas: Legal Status & Provider Guide (2026)

Quick Answer

Retatrutide is a prescription substance in the United States. Retatrutide is an investigational triple-receptor agonist (GIP/GLP-1/glucagon) with no FDA approval. It cannot legally be compounded under federal law. Commercial availability outside of clinical trials is not authorized by the FDA. In Texas, compounding is governed by the Texas State Board of Pharmacy (TSBP). In Texas, physician assistants and nurse practitioners with prescriptive authority can prescribe compounded medications including peptides. Prescribers must hold an active Texas license. Telemedicine prescribing of controlled substances and certain compounded medications is permitted under Texas Medical Board rules with specific conditions.

Federal Legal Status

FDA Approval Status

Not FDA-approved. Retatrutide is in Phase III clinical trials as of 2026. No NDA filed.

Compounding Pharmacy Rules (Federal)

Retatrutide is not FDA-approved and is not on any bulk substances list for compounding. It is an investigational drug in active Phase III trials. Compounding pharmacies cannot legally compound retatrutide under federal law. Providers offering it outside of a formal clinical trial operate without federal regulatory authorization.

Also Known As

LY3437943

Primary Research Areas

Weight loss
Obesity management
Metabolic syndrome
Type 2 diabetes

Texas Pharmacy Board & Compounding Rules

Regulator

Texas State Board of Pharmacy (TSBP)

Compounding Overview

Texas is home to one of the largest compounding pharmacy industries in the country, with detailed rules set by the Texas State Board of Pharmacy (TSBP). Texas 503A pharmacies may compound non-FDA-approved peptides under certain conditions, though federal FDA guidance takes precedence for pharmacies participating in the national regulatory framework. Texas-specific rules address sterile compounding standards, USP 797 compliance, and registration requirements for non-resident pharmacies shipping into the state.

Notable Rules

Texas TSBP requires sterile compounding facilities to comply with USP 797 standards.
Non-resident (out-of-state) pharmacies shipping compounded products into Texas must be registered with the TSBP.
Texas prohibits the sale of prescription-only compounded products without a valid prescription.
The Texas Medical Board regulates prescribing standards for telemedicine encounters including peptide programs.

Prescribing Requirements in Texas

In Texas, physician assistants and nurse practitioners with prescriptive authority can prescribe compounded medications including peptides. Prescribers must hold an active Texas license. Telemedicine prescribing of controlled substances and certain compounded medications is permitted under Texas Medical Board rules with specific conditions.

About Retatrutide

Retatrutide (LY3437943) is a triple agonist targeting GIP, GLP-1, and glucagon receptors, developed by Eli Lilly. Phase II trials reported average weight loss of approximately 24% at the highest dose over 48 weeks. Phase III trials are ongoing as of 2026.

For more research information, mechanism of action, and provider availability, see the Retatrutide research profile on PeptideBase.

Frequently Asked Questions

Is retatrutide available to the public?: Retatrutide is not FDA-approved and is not legally available outside of clinical trials. Some providers may offer it under research or "off-label investigational" frameworks, but this carries significant legal and safety risk. Verify any provider's authorization carefully.
When might retatrutide receive FDA approval?: Phase III trials are ongoing as of 2026. FDA approval, if granted, would follow Phase III completion and NDA review — typically 1–3 years after Phase III initiation. Monitor ClinicalTrials.gov for updates.

Retatrutide Providers in Texas

1 provider in the PeptideBase directory offer Retatrutide in Texas. Always verify current offerings directly with the provider.

Clinic
Performance & Wellness Center
Austin, United States
Fat LossPerformance+2
Performance & Wellness Center offers telemedicine-based hormone optimization, peptide therapy, medical weight loss, and IV infusion services. The clinic provides testosterone therapy, vitamin and peptide treatments targeting energy and recovery, and medical-grade IV therapy for various wellness goals. Services are delivered through virtual consultations with provider oversight and personalized treatment plans.
Verified4.529GoogleView →

View all Retatrutide providers nationwide →

Retatrutide Legal Status in Other States

Pharmacy board rules and compounding regulations vary by state. Compare Retatrutide legal status across other major markets:

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Content review: This educational overview is prepared by the PeptideBase editorial team and reviewed for factual accuracy. Reviewer byline coming soon (gated on 4.4). Last updated: May 10, 2026.